- GlobeNewswire•22 hours ago
NORCROSS, Ga., Aug. 25, 2016-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, announces interim results from an exploratory, open-label, Phase 2 a clinical ...
- GlobeNewswire•17 days ago
Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September. Australian patent allowance strengthens global intellectual property franchise. ...
- GlobeNewswire•24 days agoGalectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
NORCROSS, Ga., Aug. 02, 2016-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the completion of patient recruitment ...
Galectin Therapeutics, Inc. (GALT)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Ask||2.20 x 500|
|Day's Range||1.70 - 1.85|
|52wk Range||1.08 - 3.25|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.99|
|Avg Vol (3m)||119,735|
|Dividend & Yield||N/A (N/A)|